Back to School: How biopharma can reboot drug development. Access exclusive analysis here
After market close, VXGN and Raven (South San Francisco, Calif.) said they will merge in a stock deal. Raven stockholders will receive 32 million
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury